Tuesday, November 29, 2011

MS Society of Canada announces $3.8 million to study progressive forms of multiple sclerosis

November 29, 2011 - Toronto - The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation announced a $3.8 million grant to investigate the complex interplay between degeneration and inflammation in multiple sclerosis (MS). The grant will fund a study led by Dr. Peter Stys from the University of Calgary’s Hotchkiss Brain Institute, which would investigate damage that occurs in MS prior to inflammation. This research may have special relevance for those with progressive forms of MS.

Collaborative grants funded by the MS Scientific Research Foundation support large, innovative, multi-centre studies that will lead to major advances in the field of multiple sclerosis. Key collaborators of the study include colleagues from the University of Calgary, the University of British Columbia, and Laval University and the VU University in Amsterdam. The MS Scientific Research Foundation receives the majority of its funding from the MS Society of Canada.

To date, researchers have largely attributed central nervous system (CNS) damage in MS to an autoimmune attack in which inflammation causes the hallmark patches of demyelination (also called plaques or lesions).

“This study hypothesizes that the inflammatory response in MS is the resultof an underlying degenerative process rather than the primary cause of injury,” says Dr. Peter Stys, lead researcher, Department of Clinical Neurosciences, University of Calgary. “In other words, an underlying mechanism causes degeneration that prompts the inflammatory process, which in turn causes more degeneration.”
In general, progressive disease is characterized by a non-inflammatory neurodegenerative process. Approximately 10 per cent of people with MS are diagnosed with primary progressive MS. A more common type of progressive MS is secondary progressive MS – which begins as relapsing remitting MS, but then transitions to a progressive course. Fifty per cent of those with an initial diagnosis of relapsing MS eventually develop secondary progressive MS within ten years of diagnosis.

“The important roles of autoimmunity and the damage of inflammation are undeniable. But this doesn’t mean that this is the starting point. If we can understand more about the earliest triggers in the disease processes in MS, we might learn how to intervene and prevent the damage that occurs prior to an inflammatory response,” Dr. Stys says. “This research could provide information that benefits both relapsing remitting and progressive forms of MS.”

Currently in Canada, there are seven disease-modifying treatments approved for relapsing forms of MS. However, despite best efforts, little progress has been made to date in the disease management of primary progressive MS or secondary progressive MS without relapses.

“We urgently need research that tackles the challenges unique to the progressive forms of MS,” says Karen Lee, vice-president of research, MS Society of Canada. “Our hope is that Dr. Stys and his team of research collaborators will help us find answers. Can we identify the mechanisms that cause damage associated with progressive MS? Will the results lead to the development of new therapies that prevent, delay or slow progressive MS? This research may help answer these questions.”

“There are often good news stories about treatments for relapsing-remitting MS and little to hope for with respect to progressive MS,” says Michelle Amerie, who was diagnosed with MS over thirty years ago. “It’s a relief to know that researchers from across the country are working together to try and understand the progressive form of MS. It makes me feel supported, gives me some hope.”

While there are currently no effective medical treatments for progressive MS without relapses, it is possible to alleviate many symptoms, to improve some functions, and compensate for disabilities and thus improve quality of life. Visit the MS Society of Canada website for more information: mssociety.ca/en/help/types_prog.htm

About multiple sclerosis and the Multiple Sclerosis Society of Canada
Multiple sclerosis is a chronic, often disabling disease of the brain and spinal cord. It is the most common neurological disease of young adults in Canada. Most people with MS are diagnosed between the ages of 15 and 40, and the unpredictable effects of MS last for the rest of their lives. The MS Society provides services to people with MS and their families and funds research to find the cause and cure for this disease. Please visit mssociety.ca or call 1-800-268-7582 to make a donation or for more information.

About the Multiple Sclerosis Scientific Research Foundation
The Foundation is related to the MS Society of Canada, which is its main funding source. The foundation funds large, innovative, multi-centre collaborative studies that will lead to major advances in the field of multiple sclerosis. It is a unique Canadian resource.

About the Faculty of Medicine at the University of Calgary
UCalgary’s Faculty of Medicine is a national leader in health research with an international reputation for excellence and innovation in health care research, education and delivery. The Faculty of Medicine trains the next generation of health practitioners and move new treatments and diagnostic techniques from the laboratory bench to the hospital bedside, improving patient care. For more information, visit medicine.ucalgary.ca or follow them on twitter.com

About the Hotchkiss Brain Institute
The Hotchkiss Brain Institute at UCalgary, consists of more than 100 physicians and scientists who are dedicated to advancing neurological and mental health research and education. The Institute’s research strengths in foundational neuroscience (axon biology and regeneration, cerebral circulation, neural systems and behaviour) are leading to new treatments for neurological and psychiatric disorders, aimed at improving quality of life and patient care. More information on the Hotchkiss Brain Institute can be found at www.hbi.ucalgary.ca.

Bookmark and Share
Enhanced by Zemanta

Saturday, November 26, 2011

A map of Ontario highlighting OttawaImage via WikipediaPlan to cut salt intake sent back to drawing board

Ottawa to fund trials into controversial MS therapy



Bookmark and Share
Enhanced by Zemanta

Thursday, November 17, 2011

National SickKids-led study finds new way to predict MS diagnosis in children

National SickKids-led study finds new way to predict MS diagnosis in children
TORONTO - Early MRI scans can help predict the diagnosis of multiple sclerosis (MS) in children, which may permit earlier initiation of treatment, according to a new national study. The study was led by The Hospital for Sick Children (SickKids) and was performed as a part of the Canadian Pediatric Demyelinating Disease Network, a 23-site study that includes all paediatric health-care facilities in Canada. The study is published in the November 7 advance online edition of Lancet Neurology.
MS is an autoimmune disease that affects the brain and spinal cord. People with MS develop lesions (patches of inflammation in the central nervous system (CNS)) in which the neurons have been stripped of their myelin (insulating fatty protein).
In this study, the investigators created a rigorous scoring tool that was applied to magnetic resonance imaging (MRI) scans from paediatric patients following their first acute CNS demyelinating attack.
An acute CNS demyelinating attack could involve a variety of symptoms, including loss of vision, tingling in lower limbs, inability to walk, loss of balance or even paralysis. Previously, established criteria have required clinicians to wait until the occurrence of a second attack to make the diagnosis of MS. A second attack could occur as early as a month after the initial attack or many years later. Although the time to a second attack may take months to years, ongoing disease activity occurs even between attacks. Identifying children with MS through analysis of MRI scans obtained at the first acute attack can lead to rapid diagnosis and to an opportunity to offer treatment even before a second attack.
Dr. Brenda Banwell, Principal Investigator of the study, Staff Neurologist and Senior Associate Scientist at SickKids, notes that while MRI has been used on adults in this manner, “this is the first time anyone has applied an MRI scoring tool to MRI scans from a population of at-risk paediatric patients. The study demonstrates...read more

Bookmark and Share
Enhanced by Zemanta

Monday, November 7, 2011

Saffron can help cure multiple sclerosis:
Researchers at the University of Alberta who studied the ingredient, crocin, in lab models and cell cultures found that it prevents damage to cells that make myelin in the brain.

Crocin exerts a "protective effect" in brain cell cultures and other models of multiple sclerosis (MS), said Dr Chris Power who led the research.

"It prevented damage to cells that make...http://news.in.msn.com/international/article.aspx?cp-documentid=5574083

Bookmark and Share
Enhanced by Zemanta

Wednesday, November 2, 2011

University of California, San Francisco, a research team has reported on the findings of a Phase II trial of an experimental drug called ocrelizumab, which shows promise in treating multiple sclerosis. Hauser noted that the study results are “extremely exciting, both in terms of the prospect of improved therapy for people with multiple sclerosis but also for the lessons that it teaches us about the fundamental cause of the disease.”
The new study evaluated ocrelizumab in 220 individuals with multiple sclerosis who were divided into four groups: two received injections of the experimental drug at two different doses, one received the standard multiple sclerosis drug interferon-beta, and one was given a placebo.
Using magnetic resonance imaging (MRI), the investigators followed the progression of the treatment by evaluating the number of lesions observed in the brain scans and the severity and frequency of the symptoms. Overall, the patients

Bookmark and Share
Enhanced by Zemanta